Back to results

CompletedPhase 3

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

NCT00753896

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Mesa, Arizona, United States

+25 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2008-10
Enrollment: 134 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (26)

Research SiteMesa, Arizona, United States
Research SiteTempe, Arizona, United States
Research SiteConcord, California, United States
Research SiteFresno, California, United States
Research SiteLa Mesa, California, United States
Research SiteAtlanta, Georgia, United States
Research SiteIdaho Falls, Idaho, United States
Research SiteBowling Green, Kentucky, United States
Research SiteCorvallis, Oregon, United States
Research SiteChattanooga, Tennessee, United States
Research SiteMemphis, Tennessee, United States
Research SiteNew Westminster, British Columbia, Canada
Research SiteAjax, Ontario, Canada
Research SiteCambridge, Ontario, Canada
Research SiteWindsor, Ontario, Canada
Research SiteChihuahua City, Chiuahua, Mexico
Research SiteMonterrey, Nuevo León, Mexico
Research SiteDistrito Federal, Mexico
Research SiteBaia Mare, Romania
Research SiteBrasov, Romania
Research SiteBucharesti, Romania
Research SiteCraiova, Romania
Research SiteIași, Romania
Research SiteSuceava, Romania
Research SiteJohannesburg, South Africa
Research SitePretoria, South Africa

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin — TrialFind